Published in Cancer Weekly, September 7th, 2004
Investors also will receive 5-year warrants to purchase approximately two million shares of common stock at an exercise price of $4.20. The proceeds from the transaction will be used for general corporate purposes, including clinical trials and research and development. Rodman & Renshaw acted as the placement agent for the transaction.
Pro-Pharmaceuticals, Inc. (Amex:PRW)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.